Lifetime Cancer Risks of PTEN Mutation Carriers--Response
We thank Daniels and colleagues for their comments on our report ([1][1]). Given that the Cleveland Clinic is the main referral center of patients with germline PTEN mutations in the United States, it is certainly possible that ascertainment bias may exist, an issue we acknowledged in our report.
Objective ::: This pilot study was launched to explore the utility of positron emission tomography scans, at the time of diagnosis, for clinical outcomes in patients with primary extranodal non-Hodgkin’s lymphoma (PENHL) in the head and neck, retrospectively.